メタンスルホン酸エステルと他制癌剤の免疫反応に対する効果の比較

抄録

Oral or intraperitoneal administration of bis(3-methylsulfonyloxypropyl)amine p-toluenesulfonate (864-T) and N-methyl-N, N-bis(3-methylsulfonyloxypropyl)amine 4, 4'-biphenyldisulfonate (838-D) for 3 consecutive days before or after immunization suppressed the number of 19S hemolysin plaque-forming cells (HPFC) in the spleen as well as the circulating antibodies, hemagglutinin and hemolysin, of mice on day 4 after immunization with sheep red blood cells. In single administration, the maximum inhibition was found on day 0 in 864-T and 838-D, on day 2 in cyclophosphamide, and on day 3 in busulfan. 864-T and 838-D were classified in the different type from cyclophosphamide or busulfan. Seven-S HPFC were not suppressed by 864-T, 838-D, nitrogen mustard N-oxide, busulfan, or 6-mercaptopurine in the administration for 3 consecutive days from day 0 or from day 4, and only cyclophosphamide inhibited it when administered from day 4. 864-T and 838-D did not affect the carbon clearance in mice.